ReviewJournal of industrial microbiology & biotechnology2014
Importance of microbial natural products and the need to revitalize their discovery.
Review in Journal of industrial microbiology & biotechnology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 150 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
150 citing papers in PubMed, 432 citations in OpenAlex.
- Fine-grained structural classification of biosynthetic gene cluster-encoded products.Bioinformatics (Oxford, England) · 2026Article
- The WormFood CURE: Screening for bioactive metabolites that antagonize thebioRxiv : the preprint server for biology · 2026Article
- Exploring the In Vitro Antibacterial Properties of Milicia regia and Entandrophragma angolensis: Insight Into Their Antibiofilm and Efflux Pump Inhibitory Activities.TheScientificWorldJournal · 2026Article
- Microbial metabolites as engines of behavioral variation across animals.Gut microbes · 2025Review
- Emerging strategies to enhance microbial natural product-based drug discovery.Current opinion in biotechnology · 2025Review
- Polyamine Induction of Secondary Metabolite Biosynthetic Genes in Fungi Is Mediated by Global Regulator LaeA and α-NAC Transcriptional Coactivator: Connection to Epigenetic Modification of Histones.Molecules (Basel, Switzerland) · 2025Review
- A novel endophytic species, Streptomyces colwelliae sp. nov., isolated from root nodule of Alnus glutinosa.BMC microbiology · 2025Article
- iCASRED, a scarless DNA editing tool inSynthetic and systems biotechnology · 2025Article
- Microbial secondary metabolites: advancements to accelerate discovery towards application.Nature reviews. Microbiology · 2025Review
- A guide to genome mining and genetic manipulation of biosynthetic gene clusters in Streptomyces.Journal of microbiology (Seoul, Korea) · 2025Article
- Context matters: assessing the impacts of genomic background and ecology on microbial biosynthetic gene cluster evolution.mSystems · 2025Review
- Selection for toxin production in spatially structured environments increases with growth rate.The ISME journal · 2025Article
- Assessing Normandy Soil Microbial Diversity for Antibacterial Activities Using Traditional Culture and iChip Methods.Microorganisms · 2024Article
- High-Throughput Mining of Novel Compounds from Known Microbes: A Boost to Natural Product Screening.Molecules (Basel, Switzerland) · 2024Review
- Insights into docking in megasynthases from the investigation of the toblerolRSC chemical biology · 2024Article
- Article
- Mining Biosynthetic Gene Clusters ofMicroorganisms · 2024Article
- A flexible, modular and versatile functional part assembly toolkit for gene cluster engineering inSynthetic and systems biotechnology · 2024Article
- A proteomic landscape of pharmacologic perturbations for functional relevance.Journal of pharmaceutical analysis · 2024Article
- Article
90 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microbes are the leading producers of useful natural products. Natural products from microbes and plants make excellent drugs. Significant portions of the microbial genomes are devoted to production of these useful secondary metabolites. A single microbe can make a number of secondary metabolites, as high as 50 compounds. The most useful products include antibiotics, anticancer agents, immunosuppressants, but products for many other applications, e.g., antivirals, anthelmintics, enzyme inhibitors, nutraceuticals, polymers, surfactants, bioherbicides, and vaccines have been commercialized. Unfortunately, due to the decrease in natural product discovery efforts, drug discovery has decreased in the past 20 years. The reasons include excessive costs for clinical trials, too short a window before the products become generics, difficulty in discovery of antibiotics against resistant organisms, and short treatment times by patients for products such as antibiotics. Despite these difficulties, technology to discover new drugs has advanced, e.g., combinatorial chemistry of natural product scaffolds, discoveries in biodiversity, genome mining, and systems biology. Of great help would be government extension of the time before products become generic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.